Home >> Cardiovascular >> Cardiovascular >> Baby Food >> Technology & Media >>

Venous Thromboembolism - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 80 | Code: MRS - 18254

Venous Thromboembolism - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Venous Thromboembolism - Pipeline Review, H1 2015’, provides an overview of the Venous Thromboembolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous Thromboembolism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Venous Thromboembolism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Venous Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Thromboembolism Overview 7
Therapeutics Development 8
Pipeline Products for Venous Thromboembolism - Overview 8
Pipeline Products for Venous Thromboembolism - Comparative Analysis 9
Venous Thromboembolism - Therapeutics under Development by Companies 10
Venous Thromboembolism - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Venous Thromboembolism - Products under Development by Companies 14
Venous Thromboembolism - Companies Involved in Therapeutics Development 15
Bayer AG 15
Daiichi Sankyo Company, Limited 16
Gamma Therapeutics, Inc. 17
GlycoMimetics, Inc. 18
Green Cross Corporation 19
Isis Pharmaceuticals, Inc. 20
Portola Pharmaceuticals, Inc. 21
Regado Biosciences, Inc. 22
Sanofi 23
Venous Thromboembolism - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
betrixaban - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
edoxaban tosylate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Gammarin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GCC-2107 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GMI-1271 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ISIS-FXIRx - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Lysimab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
REG-2 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
rivaroxaban - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
semuloparin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Venous Thromboembolism - Recent Pipeline Updates 50
Venous Thromboembolism - Dormant Projects 69
Venous Thromboembolism - Discontinued Products 70
Venous Thromboembolism - Product Development Milestones 71
Featured News & Press Releases 71
Apr 15, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland 71
Mar 06, 2015: NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots 72
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 73
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 74
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 75
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 76
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 76
Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 77
Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) 77
Jun 23, 2014: Regado Biosciences REG2 Demonstrates Dose and Concentration Dependent Suppression of Thrombin Generation 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables
Number of Products under Development for Venous Thromboembolism, H1 2015 8
Number of Products under Development for Venous Thromboembolism - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Venous Thromboembolism - Pipeline by Bayer AG, H1 2015 15
Venous Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 16
Venous Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H1 2015 17
Venous Thromboembolism - Pipeline by GlycoMimetics, Inc., H1 2015 18
Venous Thromboembolism - Pipeline by Green Cross Corporation, H1 2015 19
Venous Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 20
Venous Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H1 2015 21
Venous Thromboembolism - Pipeline by Regado Biosciences, Inc., H1 2015 22
Venous Thromboembolism - Pipeline by Sanofi, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Venous Thromboembolism Therapeutics - Recent Pipeline Updates, H1 2015 50
Venous Thromboembolism - Dormant Projects, H1 2015 69
Venous Thromboembolism - Discontinued Products, H1 2015 70

List of Figures
Number of Products under Development for Venous Thromboembolism, H1 2015 8
Number of Products under Development for Venous Thromboembolism - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Top 10 Molecule Types, H1 2015 31
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing